However, 3-BrPA and PRIMA-1 could strongly synergize to specifically eradicate the mutant p53-carrying T24 and T24-X cells (Fig. 3), therefore shaping a novel and promising preclinical platform for bladder cancer therapy. The gene discussed is TP53; the disease is urinary bladder cancer.